RA Capital Management is a multi-stage investment firm primarily focused on evidence-based investing in healthcare, biotechnology, and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm also invests in planetary health, supporting companies from discovery through commercialization in both public and private markets.
76% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $115.0M (across 100 rounds with reported amounts).
Portfolio
103
Fund Size
$12.6B
Top Stage
Series B
Last 12 Mo
17
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
103 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Stipple Bio, Inc. | Series A | $100M | Apr 2026 |
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
| SSlate Medicines | Series A | $130M | Feb 2026 |
| IILiAD Biotechnologies | Series B | $115M | Feb 2026 |
 Avalanche Energy | Series A | $29M | Feb 2026 |
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| EEvodiaBio | Unknown | $6M | Dec 2025 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Artios Pharma Limited | Series D | $115M | Nov 2025 |
 Bambusa Therapeutics | Series A | — | Nov 2025 |
 Electra Therapeutics | Series C | $183M | Oct 2025 |
| RRani Therapeutics | Series C | $60.3M | Oct 2025 |
 Adcytherix | Series A | $105M | Oct 2025 |
 Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
| SSAB Biotherapeutics, Inc. | Series B | $175M | Jul 2025 |
 Commons Clinic | Series B | $26M | Jun 2025 |
 SpyGlass Pharma | Series D | $75M | Jun 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
 Surrozen, Inc. | Series D | $175M | Mar 2025 |
 Curevo Vaccine | Series B | $110M | Mar 2025 |
| Bambusa Therapeutics | Series A | $90M | Feb 2025 |
| VVerdiva Bio | Series A | $410M | Jan 2025 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Evommune, Inc. | Series C | $115M | Oct 2024 |
Page 1 of 5
Top Co-Investors
OrbiMed19 shared
Janus Henderson Investors16 shared
Logos Capital12 shared
Perceptive Advisors10 shared
Atlas Venture10 shared
Invus9 shared
Surveyor Capital9 shared
Vivo Capital8 shared
Samsara BioCapital8 shared
Novo Holdings8 shared
Bain Capital Life Sciences7 shared
Deerfield7 shared
Nextech Invest6 shared
Deep Track Capital6 shared
Avidity Partners6 shared
Wellington Management6 shared
BVF Partners LP6 shared
Cormorant Asset Management5 shared
GV (Google Ventures)5 shared
Soleus Capital5 shared
Last updated: 12 April 2026